How to Evaluate a Mission Pet Health Offer in 2026

Key takeaways

• Mission Pet Health is one of the largest PE-backed veterinary platforms in the US — the post-merger combined entity of Southern Veterinary Partners and Mission Veterinary Partners, backed by Shore Capital Partners and Silver Lake, with 750-plus hospitals at its 2025 launch and over 930 locations by May 2026.
• A direct offer from any buyer is not a market price. It reflects the leverage the buyer perceives in a one-on-one conversation. The only way to know how to evaluate a Mission Pet Health offer is to benchmark it against competing bids from a structured process with multiple qualified buyers.
• The headline number is not the check you take home. Break every offer into its components — cash at close, rollover equity in the platform, earnout tied to post-close performance, and any seller note — before comparing it to anything else.
• Non-financial terms matter as much as price for most sellers: your employment agreement, clinical autonomy, name and brand preservation, associate retention, and real estate all shape what the next several years of your life actually look like.
• Normalize your EBITDA before you evaluate any number. The multiple is applied to your earnings — if your earnings are wrong, the multiple is meaningless. Clean financials are the foundation of the comparison.

The call came on a Tuesday afternoon. One of our clients told me about it over dinner a few weeks later.

Mission Pet Health’s acquisition team had reached out directly, told her she had a great practice, and put a number in front of her.

It was a solid number. She was flattered.

She almost said yes the following week.

What she said instead was: “I want to know if this is actually the right number.” That instinct is the most valuable thing I see in the sellers who come out ahead.

Here is the pattern I see consistently, across the practice sales I have been part of: the first offer any major buyer puts in front of a seller is calibrated to what they believe a seller will accept in a direct conversation, not to what the practice would clear in a competitive market. That gap is rarely small.

On a well-run multi-doctor general practice, it can be several turns of EBITDA — which on a million-dollar earnings base is several million dollars.

How to evaluate a Mission Pet Health offer is the right question to ask. It requires understanding what Mission Pet Health is and how they operate, how to read the structure of their offer, and how to benchmark that offer against what the rest of the market will actually pay.

This piece answers all three.

Who is Mission Pet Health and how did they get here?

Mission Pet Health is the post-merger combined entity of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP). The merger closed in late 2024.

The unified brand launched publicly on July 21, 2025, with a new digital presence that went live August 4, 2025.

At launch, Mission Pet Health operated 750-plus hospitals across the United States, making it one of the largest PE-backed veterinary platforms in the country. By May 2026, the platform had grown to over 930 locations.

The PE sponsors behind Mission Pet Health are Shore Capital Partners — the original private equity backer of Southern Veterinary Partners — and Silver Lake, which provided recapitalization capital for the combined entity. The transaction was reported at approximately $8.6 billion in enterprise value, reflecting the scale and earnings profile of the combined platform.

Per Octus’s coverage of the deal, the combined entity carried roughly $580 million in EBITDA and approximately $2.9 billion in revenue at close.

The CEO of Mission Pet Health is Dr. Jay Price, a veterinarian who founded the MVP predecessor entity in 2014.

The organization’s stated mission is to support veterinarians with what it calls medical autonomy alongside the best back-office support — an acquisition model that emphasizes preserving local practice identity and clinical independence.

That context matters when you are sitting across from a Mission Pet Health term sheet. You are dealing with one of the most active and well-capitalized buyers in the market.

The scale they operate at means they have a view on practice values across hundreds of deals. You need an equally informed view on yours before you respond.

How to evaluate a Mission Pet Health offer in 2026: the four layers

A Mission Pet Health offer — like any major buyer’s offer — has four layers. Evaluating it properly means reading all four, not just the headline.

Layer 1: What is the multiple applied to — and is your EBITDA right?

The offer is almost always expressed as a price, which is built on a multiple of EBITDA — what your practice earns in pure operating profit, before taxes and accounting choices. The multiple is the multiplier buyers apply to that profit number to set the price.

Before you can assess whether the multiple is fair, the EBITDA has to be correct. That means normalized EBITDA — the same profit number after stripping out personal expenses you run through the practice: owner vehicles, family on payroll above market, owner compensation above what a hired medical director would cost, and one-time non-recurring items.

When a buyer’s team tells you they want to see your books, they are calculating their own version of normalized EBITDA. If that number is different from what you think your practice earns, the offer can look different from what you expected — higher or lower depending on whose number is more accurate.

The single most important thing you can do before engaging with any buyer is arrive at a defensible, documented normalized EBITDA of your own. That is the number everything else is built on.

For context on how this market is pricing practices: per Octus’s 2025 coverage of the veterinary credit markets, GP practices as of early 2025 were generally clearing in the mid- to high single-digit EBITDA range in direct, single-bidder contexts. Competitive processes with multiple qualified buyers typically produce meaningfully better outcomes — we cover the mechanics of that gap in our piece on how much private equity is paying for veterinary practices.

Layer 2: What does the total deal value actually consist of?

The number a buyer leads with is a total deal value. What matters is how that total is divided.

Per industry M&A commentary from Octus and Capstone Partners, PE-backed buyer offers in this market commonly allocate the majority of total deal value to cash at close, with the remainder split across some combination of rollover equity, earnout, and occasionally a seller note. The specific split in any given deal is negotiated case by case.

Rollover equity — keeping a slice of ownership in the new combined entity instead of taking all cash at close — is a common component of large-platform offers. The value of that rollover equity is realized at the platform’s eventual exit or recapitalization, which could be years away and depends on how the platform performs in the interim.

An earnout — a portion of the sale price paid after closing, contingent on the practice hitting agreed performance targets — shifts value into the future and ties it to conditions you will need to meet after the sale. Revenue-based earnout targets are generally preferable to EBITDA-based ones, because the seller has more direct control over revenue than over EBITDA in the post-close operating environment.

The cash you actually receive on closing day can differ significantly from the stated total. Before you compare Mission Pet Health’s offer to anything else, build a side-by-side table: cash at close, rollover equity (with realistic liquidity assumptions), earnout (at conservative and optimistic cases), and any seller note.

That is the apples-to-apples starting point.

Deal component	What it is	What to watch
Cash at close	Funds wired directly to you on closing day	This is the most certain value in the deal
Rollover equity	Ownership retained in the new platform	Value depends on platform performance and exit timing — illiquid until an exit event
Earnout	Performance-contingent deferred payment	What are the targets? Who controls the inputs? Revenue vs EBITDA?
Seller note	Deferred payment obligation from the buyer	Terms, interest, and default provisions matter
Headline total	Sum of all components	Rarely the after-tax check you actually receive

Layer 3: What are the non-financial terms?

Most sellers come to regret focusing exclusively on price. The non-financial terms shape everything about what the next 3 to 5 years of your working life look like.

Your employment agreement. What compensation is being offered? For how long?

What are the conditions of your continued employment and the consequences of early departure? This deserves as much attention as the purchase price.

Clinical autonomy. Mission Pet Health‘s stated position, per their partnerships materials, is that they will not tell you how to practice veterinary medicine. They pledge not to change your practice’s name, brand, or logo.

The specific terms of these commitments in your actual agreement need to be reviewed by independent legal counsel — general platform promises and specific contract language sometimes differ.

Associate and staff retention. What happens to your team? Key associate veterinarians and long-tenured staff are part of the goodwill you are selling.

How the buyer treats them post-close affects both the transition and your earnout performance.

Real estate. If you own the building, what is the buyer’s proposal for the property? A sale-leaseback arrangement — selling the real estate separately and leasing back — has its own valuation dynamics and can affect your net proceeds significantly.

We cover this in our veterinary practice sale-leaseback guide.

Layer 4: The tax consequences of how the price is allocated

The way the purchase price is allocated across asset classes determines how much of the deal you actually keep. Goodwill is generally taxed at long-term capital gains rates, which run meaningfully lower than ordinary income rates.

Equipment and other tangible assets sold above their tax basis are generally taxed as ordinary income.

For sellers organized as C corporations, the entity structure creates additional complexity around goodwill allocation and potential double taxation that requires early planning. We go deeper on this in our veterinary practice tax guide.

The point is that tax analysis belongs at the term sheet stage, not after the deal is signed. The buyer’s allocation preferences and yours may differ.

Having your CPA and attorney involved early gives you room to negotiate on this.

Why the competitive process is the only benchmark that matters in 2026

Here is what I tell every owner who contacts us after receiving a direct outreach offer: the offer you are holding tells you what one buyer thinks they can get away with paying in a one-on-one conversation. It doesn’t tell you what the market will pay.

Those two numbers are not the same.

Capstone Partners‘ April 2026 Pet Sector M&A Update recorded 18 announced or completed pet sector transactions in YTD 2026, compared to 8 in the same period the prior year. The vet and health segment accounted for 9 of those deals.

The pace of deal activity signals that qualified buyers are actively underwriting practices right now — which means competition is achievable for the right practice.

What a competitive process does is create parallel underwriting pressure. When 4 to 6 vetted, qualified buyers look at the same practice in the same window, each knowing the others are there, the offer dynamics change.

Buyers who want the asset have to put their best terms forward, not just a calibrated-to-what-the-seller-will-accept number.

The Elite Selling System is how we run that process. We hand-select and vet every buyer who gets to bid on your practice — the way a doorman with a velvet rope lets in only the right people — then open a private competitive window inside that group.

That structure is what moves the multiple, and because a practice’s price is largely goodwill, moving the multiple moves the number that matters most.

Mission Pet Health has been one of the most active acquirers in the market since the late 2024 merger close. In the processes where they participate as a bidder, competitive outcomes for strong general practices reflect what the platform’s underwriting actually supports, not what they offered in a first direct conversation.

That distinction is where the real money is.

We cover the full mechanics of the sale process in our guide to selling a veterinary practice and the earnout and rollover equity guide.

What the 2026 market context means for your offer evaluation

Today’s Veterinary Business called 2025 “Year 3 of the Great Compression” — a period where the large platforms that spent 2020 to 2022 acquiring aggressively are now focused on operational efficiency and margin rebuilding. That shift matters when you are evaluating any offer.

A platform that is managing a 930-location network while servicing significant debt at its holding company level is balancing acquisition appetite against operational demands. Per Octus’s 2025 credit market coverage, the platform-level debt structure for large veterinary rollups has created meaningful credit dispersion across VSOs, with fair values ranging from 88 to 101 percent of par across the sector.

None of this means Mission Pet Health is not a serious buyer — they clearly are. It does mean that understanding the buyer’s own financial position and strategic priorities gives you useful context when you read their offer.

A buyer who is focused on consolidating existing practices may underwrite additions differently than a buyer who is in pure-growth mode.

The New York State Assembly Bill 9042, which proposes attorney general review of veterinary M&A transactions above a $200,000 materiality threshold, is one example of a regulatory development that could affect how national platforms approach acquisitions in certain markets. Know the regulatory environment in your state before you get to the term sheet.

For practices of scale in the $2M+ revenue range we focus on, the most relevant data point is what your specific practice clears in a competitive process where Mission Pet Health and the other major buyers compete on the same terms. That number is the only market-validated answer to the question this article is built around.

The six questions to answer before you respond to a Mission Pet Health offer

If you have an offer on your desk right now, here are the six questions that need answers before you respond — to Mission Pet Health or to any major buyer.

First: What is my normalized EBITDA, independently calculated? Not the buyer’s version. Your own, documented, defensible number.

The multiple is applied to this figure. If it is wrong, everything downstream is wrong.

Second: What is the cash-at-close component? Not the total deal value. The cash that arrives on closing day.

That is the most certain value in the deal, and it is the number to anchor to.

Third: What are the rollover equity terms? What platform are you rolling into, at what valuation, with what liquidity provisions? How long until the sponsor expects an exit, and what happens to the rollover if performance deteriorates?

Fourth: What are the earnout mechanics? Revenue or EBITDA targets? What is the measurement period?

Who controls the inputs? What happens if the platform changes how revenue is attributed after close?

Fifth: What do the non-financial terms say about your life post-close? Read the employment term, the clinical autonomy language, the non-compete geography and duration, and the name and brand provisions.

Sixth: Have you compared this to competing bids? If not, you don’t have a market price. You have an opening offer.

What to do next

The most consistent predictor of a good outcome I see across the practice sales we run is this: the owners who ask “is this the right number?” before they respond, and who take the time to find out, almost always end up in a better place than the ones who move quickly on the first offer they receive.

The first step is knowing what your practice is actually worth — independently, before any buyer tells you their version of that number. Then knowing what the market would pay through a properly run competitive process.

Those two data points are what give you a grounded basis for evaluating a Mission Pet Health offer or any offer.

Get a Free Mission Pet Health Offer Review →

We pull your normalized EBITDA ourselves, model the structure of the offer you have received, and show you where it sits relative to what we would expect the market to pay through a competitive process. That comparison is free and there is no obligation to engage further.

The Transitions Elite engagement model is success-based — no upfront fees, no retainer — so we only get paid when a deal closes and only out of the value our process delivers above what you would have gotten on your own.

We also cover the full landscape of who is buying veterinary practices in 2026 — which matters because the right competitive process includes more than one potential buyer and the right set of bidders depends on your practice profile.

---

Frequently asked questions

How do I evaluate a Mission Pet Health offer for my veterinary practice in 2026?

Evaluating a Mission Pet Health offer in 2026 requires four steps: normalize your EBITDA so the multiple is applied to a clean number, break the offer into its components (cash at close, rollover equity, earnout, seller note), benchmark it against competing bids from a structured competitive process with multiple qualified buyers, and review non-financial terms including clinical autonomy, branding, employment, and real estate. A single direct offer from any buyer — Mission Pet Health included — cannot be assessed without a market comparison.

What is Mission Pet Health and who backs it?

Mission Pet Health is the post-merger combined entity of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP). The merger closed in late 2024 and the Mission Pet Health brand launched publicly in July 2025.

The platform is backed by Shore Capital Partners, the original private equity sponsor of SVP, and Silver Lake, which provided recapitalization capital for the combined entity. At launch, Mission Pet Health operated 750-plus hospitals across the United States.

What does a Mission Pet Health offer typically look like in 2026?

Mission Pet Health does not publish a standard acquisition price sheet. Per their partnership materials, they offer flexible deal structures tailored to individual sellers, with a stated valuation process of 30 to 45 days and target closing in 90 to 120 days.

Mission commits to preserving your practice’s name, brand, and logo. The specific structure of any offer — including cash at close, rollover equity, and earnout — is negotiated case by case and becomes visible through a competitive process with multiple buyers.

Should I accept a Mission Pet Health offer without running a competitive process?

No. A single direct offer from any buyer, including Mission Pet Health, reflects the leverage the buyer perceives in the conversation.

Without competing bids, there is no market reference point. Across the deals we have run, the gap between a single-bidder direct offer and the outcome of a structured competitive process is consistently material — often several turns of EBITDA on the same practice.

Running a competitive process is the only way to know whether Mission Pet Health’s offer reflects what the market will actually pay.

What non-financial terms matter most in a Mission Pet Health offer?

Beyond price, the terms that affect your life most after closing include your employment agreement (compensation, role, duration), clinical autonomy provisions (who controls medical decisions), branding and name preservation commitments, associate and staff retention provisions, and real estate treatment (whether the practice owns or leases the property and what happens to that arrangement at close). Mission Pet Health‘s stated policy is to preserve your practice’s name and brand and not interfere with medical decision-making, but terms vary by deal and need independent legal review before signing.

How is rollover equity valued in a Mission Pet Health deal?

Rollover equity — keeping a slice of ownership in the new combined entity instead of taking all cash at close — is valued at the platform’s eventual exit or recapitalization event, which could be years away. The value is not guaranteed and depends on how the platform performs between now and that event.

Before accepting any rollover equity component, sellers should understand the platform’s current leverage, the sponsor’s exit timeline, and what liquidity provisions (if any) are built into the rollover structure.

What is the scale of Mission Pet Health in 2026?

Mission Pet Health launched in July 2025 with 750-plus hospitals across the United States, created by the merger of Southern Veterinary Partners and Mission Veterinary Partners. By May 2026, the platform had grown to over 930 locations, making it one of the largest PE-backed veterinary operators in the country.

The platform is backed by Shore Capital Partners and Silver Lake, and had approximately $2.9 billion in revenue and around $580 million in EBITDA as of the merger close.

What questions should I ask Mission Pet Health before signing a letter of intent?

Before signing a letter of intent with Mission Pet Health or any buyer, ask: What is the normalized EBITDA you are underwriting and how did you calculate it? How is the total deal value allocated across cash at close, rollover equity, and earnout?

What are the earnout targets and how are they measured? What does my employment agreement look like and for how long?

What happens to my real estate? Who controls clinical decisions after closing?

What is your expected exit timeline for the platform? These questions belong in the term sheet stage, not after the LOI is signed.

---

Sources

Mission Pet Health — company disclosures and corporate press releases

1. Mission Pet Health. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” July 21, 2025. missionpethealth.com
2. Mission Pet Health. “Partnerships.” missionpethealth.com
3. GlobeNewswire. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” July 21, 2025. globenewswire.com
4. Silver Lake. “Mission Pet Health — Portfolio.” silverlake.com
5. Shore Capital Partners. “Mission Pet Health.” shorecp.com

Industry M&A research and valuation data

6. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
7. Octus. “Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure.” 2025. octus.com
8. Today’s Veterinary Business. “The Great Compression, Year 3.” December 2025. todaysveterinarybusiness.com
9. The Middle Market. “Shore Capital, Silver Lake Reportedly in Talks Over $8.6B Pet Care Deal.” themiddlemarket.com

Veterinary practice operations and deal structure

10. dvm360. “Merger of veterinary organizations yields a new name.” 2025. dvm360.com
11. Four Corners Property Trust. “FCPT Announces Agreement to Acquire up to 102 Mission Pet Health Veterinary Properties for $268 Million.” May 2026. businesswire.com

Legal and regulatory analysis

12. Holland & Knight. Healthcare industry regulatory commentary. hklaw.com